Navigation Links
PharmAthene Appoints Mitchel Sayare, Ph.D. to the Company's Board of Directors
Date:4/28/2010

ANNAPOLIS, Md., April 28 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced the appointment of Mitchel Sayare, Ph.D. to PharmAthene's Board of Directors, increasing the company's Board to nine members.

Dr. Sayare most recently served as Chairman and Chief Executive Officer of ImmunoGen, a publicly traded biotechnology company engaged in the research and development of antibody-based cancer therapeutics.  During his long and successful tenure with the company, he was responsible for leading a successful IPO for ImmunoGen and raising over $300 million of venture capital and public equity financing for the company.  During this time, Dr. Sayare also served as President of the 95%-owned ImmunoGen subsidiary, Apoptosis Technology, where he was responsible for managing operations for the organization.

Prior to joining ImmunoGen, Dr. Sayare served as Vice President, Development at Xenogen, Inc., a biotechnology company specializing in monoclonal antibody-based diagnostic systems for cancer.  In this role he oversaw all research and development, corporate development, and investor relations responsibilities for the company.

Dr. Sayare earned his Ph.D. in biochemistry from the Temple University School of Medicine and his undergraduate degree from Ursinus College.

"We are very pleased to have Dr. Sayare join PharmAthene's Board of Directors," commented John Pappajohn, Chairman of the Board.  "Mitch's extensive experience in the biotechnology industry – he was the first employee at ImmunoGen, provides a vast network of contacts and experiences to draw upon to assist PharmAthene in achieving its objective of being the leading provider of medical countermeasures for the nation.  As a former Director of the Biotechnology Industry Organization (BIO), Mitch is well known and respected within the biotechnology industry, and will bring an important and valuable perspective to PharmAthene."

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia® - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

For more information about PharmAthene, please visit www.PharmAthene.com.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").

Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
2. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
3. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
4. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
5. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
6. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
7. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
8. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
9. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
10. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
11. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... MENLO PARK, CA (PRWEB) , ... May 23, 2017 , ... ... announced the publication of “Label-free isolation of prostate circulating tumor cells using Vortex ... publication is the result of a collaboration with Dr. Dino Di Carlo and Dr. ...
(Date:5/23/2017)... ... 2017 , ... Customers often prefer PLC and network ... METTLER TOLEDO has released two new videos that show how they have solved ... ACT350 into Siemens and Allen Bradley PLCs is easy and fast. ...
(Date:5/21/2017)... CA (PRWEB) , ... May 20, 2017 , ... ... tool that helps avoid the lengthy trial and error process by finding the ... It can also strengthen the doctor-patient relationship through a personalized approach to ...
(Date:5/18/2017)... ... May 16, 2017 , ... Clinical Supplies Management (“CSM”), a Great Point ... continues to grow. CSM has doubled in size over the past six months ... growth strategy. , Roger Gasper joins CSM as Chief Financial Officer. Roger has ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
Breaking Biology News(10 mins):